Control of Liver Cirrhosis with Lymphosorbtion
Author Information
Author(s): Teimuraz L. Pirtzchalava, Dmitry A. Granov, Pavel G. Tarazov
Primary Institution: St. Petersburg Research Institute of Roentgenology and Radiation Therapy
Hypothesis
Can lymphosorbtion combined with medical therapy effectively control activation of liver cirrhosis?
Conclusion
Lymphosorbtion combined with medical therapy is more effective than medical therapy alone in managing liver cirrhosis complications.
Supporting Evidence
- Control of activation was achieved in 89% of patients receiving lymphosorbtion compared to 56% in the control group.
- Hospitals mortality rates were lower in the lymphosorbtion group (4%) compared to the control group (17%).
- 100% of patients in the lymphosorbtion group saw a decrease in ascites compared to 70% in the control group.
- Gastroesophageal varices decreased in diameter in 50% of the lymphosorbtion group compared to 0% in the control group.
- Encephalopathy regressed in 90% of patients in the lymphosorbtion group compared to 30% in the control group.
- The duration of hospital stay was shorter by two times in the lymphosorbtion group.
Takeaway
Doctors found that a special treatment called lymphosorbtion helps people with serious liver problems feel better faster than just medicine alone.
Methodology
Patients with liver cirrhosis received either lymphosorbtion plus medical therapy or only medical therapy, and outcomes were compared.
Limitations
The study only included patients with Child-Pugh's Class C liver cirrhosis.
Participant Demographics
28 patients in the treatment group and 30 in the control group, all with Child-Pugh's Class C liver cirrhosis.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website